Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features.
暂无分享,去创建一个
B. Escudier | Y. Loriot | K. Fizazi | C. Massard | A. Bossi | M. Gross-goupil | M. di Palma | M. Di Palma | M. Gross‐Goupil
[1] I. Tannock,et al. Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] R de Crevoisier,et al. The postchemotherapy PSA surge syndrome. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] W. Oh,et al. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone‐refractory prostate cancer who are refractory to docetaxel , 2008, Cancer.
[4] J. Pignon,et al. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. , 2007, The Lancet. Oncology.
[5] M. Gross,et al. Activity of second‐line chemotherapy in docetaxel‐refractory hormone‐refractory prostate cancer patients , 2007, Cancer.
[6] C. Sternberg,et al. Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC: Results of a randomized phase III trial , 2007 .
[7] W. Oh,et al. Response to Vinorelbine With or Without Estramustine as Second-Line Chemotherapy in Patients with Hormone-Refractory Prostate Cancer , 2007, Cancer journal.
[8] W. Oh,et al. Is there a role for platinum chemotherapy in the treatment of patients with hormone‐refractory prostate cancer? , 2007, Cancer.
[9] P. di Sant'Agnese,et al. Immunohistochemical characterization of neuroendocrine cells in prostate cancer , 2006, The Prostate.
[10] J. Manola,et al. Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes. , 2006, Urology.
[11] J. Bay,et al. Circulating chromogranin a and hormone refractory prostate cancer chemotherapy. , 2006, The Journal of urology.
[12] C. Kollmannsberger,et al. First‐ and second‐line chemotherapy with docetaxel or mitoxantrone in patients with hormone‐refractory prostate cancer , 2006, Cancer.
[13] A. Lazaris,et al. Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications. , 2005, Urology.
[14] P. di Sant'Agnese,et al. Tumorigenesis and Neoplastic Progression Differential Expression of Interleukin-8 and Its Receptors in the Neuroendocrine and Non-Neuroendocrine Compartments of Prostate Cancer , 2005 .
[15] L. Dogliotti,et al. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. , 2005, Endocrine-related cancer.
[16] P. Abrahamsson,et al. Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. , 2005, European urology.
[17] C. Tangen,et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.
[18] I. Tannock,et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.
[19] R. Matusik,et al. NE-10 Neuroendocrine Cancer Promotes the LNCaP Xenograft Growth in Castrated Mice , 2004, Cancer Research.
[20] C. Gregory,et al. Neuroendocrine cell differentiation in the CWR22 human prostate cancer xenograft: Association with tumor cell proliferation prior to recurrence , 2004, The Prostate.
[21] David C. Smith,et al. Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone‐refractory prostate carcinoma , 2003, Cancer.
[22] J. Lafitte,et al. A phase II randomised trial comparing the cisplatin-etoposide combination chemotherapy with or without carboplatin as second-line therapy for small-cell lung cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] P. Thall,et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] P. Babb,et al. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons , 2002, BJU international.
[25] P. Babb,et al. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part II: individual countries , 2002, BJU international.
[26] V. Reuter,et al. Cytotoxic Treatment of Aggressive Prostate Tumors with or without Neuroendocrine Elements , 2002, Acta oncologica.
[27] J. Shuster,et al. Results of a Randomized Phase III Trial in Children and Adolescents with Advanced Stage Diffuse Large Cell Non-Hodgkin's Lymphoma: A Pediatric Oncology Group Study , 2002, Leukemia & lymphoma.
[28] L. Dogliotti,et al. Circulating neuroendocrine markers in patients with prostate carcinoma , 2000, Cancer.
[29] B. Freidlin,et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] A. Bjartell,et al. Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment. , 1998, Urology.
[31] T. H. van der Kwast,et al. The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. , 1997, The Journal of urology.
[32] M. Stridsberg,et al. Neuroendocrine differentiation in carcinomas of the prostate: Do neuroendocrine serum markers reflect immunohistochemical findings? , 1997, The Prostate.
[33] J P Pignon,et al. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. , 1993, The New England journal of medicine.